Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio — Oct 5th, 2024

We recently compiled a list of the 10 Buzzing AI Health Stocks.In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other buzzing AI health stocks. The economic impact of AI is projected to be substantial, particularly in region...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio — Oct 5th, 2024

We recently compiled a list of the 10 Buzzing AI Health Stocks.In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other buzzing AI health stocks. The economic impact of AI is projected to be substantial, particularly in region...

Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio — Oct 5th, 2024

We recently compiled a list of the 10 Buzzing AI Health Stocks.In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other buzzing AI health stocks. The economic impact of AI is projected to be substantial, particularly in region...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio — Oct 5th, 2024

We recently compiled a list of the 10 Buzzing AI Health Stocks.In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other buzzing AI health stocks. The economic impact of AI is projected to be substantial, particularly in region...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

High Growth Tech Stocks in the United States for October 2024 — Oct 7th, 2024

In the last week, the United States market has stayed flat, yet it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looki...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Exact Sciences Schedules Third Quarter 2024 Earnings Call — Oct 8th, 2024

MADISON, Wis., October 08, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on No...

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? — Nov 6th, 2024

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Continue reading View comments...

Exact Sciences Corporation (EXAS) Bounced Back in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...